Meeting the challenge of growth and profitability

Journal of Generic Medicines

Volumn 2, Issue 4, 2005, Pages 297-307

  Tempest, Brian ^a  

^a RANBAXY LABORATORIES LTD   (India)

Author keywords

Cost; Discovery; Generics; Growth; Health; India

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; CIPROFLOXACIN; GENERIC DRUG; HYPOCHOLESTEROLEMIC AGENT; RBX 11160; ROSUVASTATIN; UNCLASSIFIED DRUG;

AGING; ARTICLE; BUDGET; CLINICAL TRIAL; COMPETITION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INDIA; MALARIA; PATENT; PHYSICAL DISEASE; PRESCRIPTION; PRODUCTIVITY; PROFIT;

EID: 23844548507     PISSN: 17411343     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940082     Document Type: Article

References (12)

1. US Bureau of Economic Analysis (2004) 'Morgan Stanley Economics Research Report', September.
2. Anon (2004) Washington Post, p. E01.
3. Deutsche Bank and SSB Research (2002).
4. OECD Health Data (2003), 3rd Edn.
5. Anon (2004) Sunday Business Post, August.
6. IMS Health (2004) MIDAS, MAT, March.
7. IMS Health (2003) 'NPA ™ Plus7, Method of Payment Report, YE 2003 National Sales Perspectives™'.
8. CSO (2004) China National Bureau of Statistics, Morgan Stanley Research, September.
9. RBI (2004) Central Statistical Organization, China National Bureau of Statistics, Morgan Stanley Economics Research Report, September.
10. (2003) CLSA Emerging Markets, Summer.
11. (2003) IPHMR Conference, New Delhi, August.
12. IPHMR Conference (2004) Nasscom-McKinsey Report, New Delhi, August.